5-HTP

Anotusi

• Masalo e aoga mo ...
• Masalo le aoga mo ...
• Le lava molimau e fuaina aoga mo ...
• Lapataiga faʻapitoa & lapataʻiga:

5-HTP (5-hydroxytr Egyptophan) o se vailaʻau o-oloa o le polotini fausia poloka L-tryptophan. O loʻo gaosia faʻapisinisi foi mai fatu o se laau Aferika ua taʻua o Griffonia simplicifolia.

5-HTP e faʻaaogaina mo le le lava o le moe e pei o le le moe, faʻanoanoa, popole, ma le tele o isi tulaga, ae leai se lelei faʻasaienisi faʻamaoniga e lagolagoina le tele o nei faʻaaoga.

Natura Faʻafomaʻi Maea Faʻamatalaga fua faatatau aoga faʻavae i luga o faʻasaienitisi faʻamaoniga e tusa ma le fua faʻatatau lenei: Aoga, Masalo Lelei Lelei, E Lelei Lelei, Masalo Lelei Lelei, Masalo Lelei, Le Lelei, ma Le lava Faʻamaoniga e Fuafua ai.

Le aoga togi mo 5-HTP e faapea:

Masalo e aoga mo ...

• Faʻanoanoa. Avea le 5-HTP ile gutu e foliga mai e faʻaleleia atili ai faʻailoga o le faʻanoanoaga i nisi tagata. O nisi suʻesuʻega o suʻesuʻega o loʻo faʻaalia ai o le inuina o le 5-HTP e ala i le gutu e ono aoga e pei o ni vailaʻau e faʻatonu ai vailaʻau mo le faʻaleleia atili o faʻanoanoaga. I le tele o suʻesuʻega, 150-800 mg i aso uma o le 5-HTP na aveina. I nisi tulaga, o maualuga maualuga na faʻaaogaina.

Masalo le aoga mo ...

• Down syndrome. O nisi suʻesuʻega faʻaalia ai o le tuʻuina atu o le 5-HTP i pepe ma Down syndrome e ono faʻaleleia atili ai maso ma gaioiga. O isi suʻesuʻega faʻaalia ai e le faʻaleleia le maso poʻo le tuputupu aʻe pe a ave mai le pepe seʻia oʻo i le 3-4 tausaga le matua. Ua faʻaalia foi i suʻesuʻega le aveina o le 5-HTP faʻatasi ai ma vailaʻau masani e masani ona faʻatonuina e faʻaleleia atili ai le atinaʻe, tomai lautele, poʻo le gagana.

Le lava molimau e fuaina aoga mo ...

• O se ituaiga o popolega faʻailogaina e mafaufauga faifai pea ma amioga toe fai (le mautonu-faʻamalosia faʻamaʻi poʻo OCD). I le amataga o suʻesuʻega, o le faʻaaogaina o le 5-HTP ma le antidepressant fualaʻau fluoxetine (Prozac) mo le 12 vaiaso e ono faʻaleleia atili ai nisi faʻailoga o le OCD.
• Le faʻaogaina o le ava malosi. O suʻesuʻega vave na faʻaalia ai o le inuina o le 5-HTP ma le D-phenylalanine ma le L-glutamine mo le 40 aso e mafai ona faʻaititia ai le faʻateʻaina o le 'ava malosi. Ae ui i lea, o le aveina o le 5-HTP ma carbidopa i aso uma mo le tasi le tausaga e foliga mai e le fesoasoani i tagata taofi le inu. O le aʻafiaga o le 5-HTP naʻo ia ava malosi e le manino.
• Faamai Alzheimer. O suʻesuʻega muamua e taʻu mai ai o le aveina o le 5-HTP e le gutu e le fesoasoani i faʻailoga o le Alzheimer faamaʻi.
• Popole. Faʻamaoniga i luga o aʻafiaga o le 5-HTP mo le popole e le manino. O le vave suʻesuʻe na faʻaalia ai o le aveina o le 25-150 mg o le 5-HTP i le gutu i aso uma faʻatasi ai ma le carbidopa e foliga mai e faʻaititia ai le popolevale faʻailoga i tagata e maua i faʻalavelave popole. Peitaʻi, o isi suʻesuʻega amata o loʻo faʻaalia ai o le maualuga o tui o le 5-HTP, 225 mg i aso taʻitasi pe sili atu, e foliga mai e atili ai ona popole. E le gata i lea, o le inuina o le 60 mg o le 5-HTP i aso uma e ala i le alatoto e le faʻaititia ai le popole i tagata e maua i faʻafitauli o le popolevale.
• Faʻaleagaina faiaʻoga e afaina ai maso gaioiga (cerebellar ataxia). Faʻamaoniga i luga o le faʻaaogaina o 5-HTP mo cerebellar ataxia e le manino. O le amataga o faʻamaoniga ua faʻaalia ai o le aveina o le 5 mg / kg o le 5-HTP i aso uma mo le 4 masina e mafai ona faʻaititia ai le faʻaleagaina o neula. Peitaʻi, o isi suʻesuʻega faʻaalia ai o le aveina o le 5-HTP i aso uma mo le oʻo atu i le tasi le tausaga e le faʻaleleia atili ai faʻailoga o le cerebellar ataxia.
• Fibromyalgia. O le vave suʻesuʻe e taʻu mai ai o le aveina o le 100 mg o le 5-HTP i le gutu faatolu taimi i aso uma mo le 30-90 aso e ono faaleleia ai le tiga, agamalu, moe, popolevale, lelava, ma le maaa o le taeao i tagata e maua i le fibromyalgia.
• Faʻailoga o menopause. O le vave suʻesuʻe e taʻu mai ai o le aveina o le 150 mg o le 5-HTP i aso uma mo le 4 vaiaso e le faʻaititia ai le vevela i fafine pe a maeʻa le vaʻaiga.
• Migraine. Faʻamaoniga i luga o aʻafiaga o le 5-HTP mo le puipuia poʻo togafitiga o migraines i tagata matutua e le manino. O nisi suʻesuʻega faʻaalia ai o le aveina o le 5-HTP i aso uma e le faʻaititia ai migraines, ae o isi suʻesuʻega faʻaalia e ono aoga e pei o vailaʻau faʻatonu. 5-HTP e foliga mai e le faʻaititia migraines i tamaiti.
• Puta tele. O le suʻesuʻe muamua e taʻu mai ai o le aveina o le 5-HTP e ono fesoasoani e faʻaititia ai le manaʻonaʻi, o le taumafaina o le kalori, ma le mamafa i tagata ua puputa. O isi suʻesuʻega o loʻo faʻapea mai, o le faʻaaogaina o se gutu faʻapitoa pasī o loʻo iai le 5-HTP ma isi tala o loʻo iai (5-HTP-Nat Exts, Medestea Biotech S.p.a., Torino, Italia) mo le 4 vaiaso e faʻateleina ai le paʻu o pauna e tusa ma le 41% i fafine ua ova le mamafa o fafine pe a maeʻa le fusuʻaga.
• Aveʻese mai heroin, morphine, ma isi fualaʻau opioid. O le vave suʻesuʻe na fautua mai ai o le aveina o le 200 mg o le 5-HTP i aso uma mo aso e 6 faʻatasi ai ma le tyrosine, phosphatidylcholine, ma le L-glutamine, e ono faʻaititia ai le le lava o le moe aʻi ma faʻateʻa faʻailoga i le toe maua mai o heroin addicts.
• Faʻamaʻi Parkinson. O suʻesuʻega muamua na faʻaalia ai o le aveina o le 100-150 mg o le 5-HTP i le gutu i aso uma ma vailaʻau masani e foliga mai e faʻaititia ai le luluina, peitaʻi o nei penefiti e faʻaauau pea e oʻo atu i le 5 masina. O isi suʻesuʻega vave na faʻaalia ai o le inuina o le 50 mg o le 5-HTP i aso uma e ono faʻaititia ai faʻailoga o faʻaletonu o le gasegase mai le vailaʻau o le levodopa, faʻapea foʻi ma faʻailoga o le faʻanoanoaga, i tagata e maua i le faʻamaʻi Parkinson. Ae o le tele o tui o 5-HTP, 275-1500 mg i aso uma, faʻatasi ai ma le carbidopa e ono faʻateteleina ai nisi faʻailoga.
• Le malie o le ulu. O le vave suʻesuʻe e taʻu mai ai o le aveina o le 100 mg o le 5-HTP tolu taimi i aso uma mo le 8 vaiaso e le faʻaititia ai le tiga poʻo le umi o le vevesi o le ulu.
• Faʻamatalaga o le le atoatoa-hyperactivity faʻaletonu (ADHD).
• Le mautonu.
• Premenstrual dysphoric maʻi (PMDD).
• Premenstrual syndrome (PMS).
• Ramsey-Hunt faʻamaʻi.
• Isi tulaga.

E tele faʻamaoniga e manaʻomia e fua ai le aoga o le 5-HTP mo nei faʻaaogaina.

O le 5-HTP e galue i le faiʻai ma le totonugalemu o neula e ala i le faʻateleina o le gaosiaina o le vailaʻau o le serotonin. Serotonin mafai ona aʻafia moe, manaʻo, vevela, amioga faʻafeusuaiga, ma lagona tiga. Talu ai o le 5-HTP faʻateleina le tuʻufaʻatasia o le serotonin, e faʻaaogaina mo le tele o faʻamaʻi e talitonuina ai le serotonin e taua tele e aofia ai faʻanoanoaga, le moe ai, ova tele, ma le tele o isi tulaga.

A ave e le gutu: 5-HTP o MAFAI ONA SAFIA pe a aveina i le gutu talafeagai. Sa faʻaaoga saogalemu i tui e oʻo atu i le 400 mg i aso uma e oʻo atu i le tasi le tausaga. Ae o nisi tagata na ave le 5-HTP ua atiaʻe se tulaga ua taʻua o le eosinophilia-myalgia syndrome (EMS). EMS o se tulaga ogaoga aofia ai soʻoga maso maso (myalgia) ma toto le masani ai (eosinophilia). Nisi tagata manatu EMS ono mafua mai i se faʻafuaseʻi elemeni poʻo faʻaleagaina i nisi 5-HTP oloa. Ae e le lava faʻamaoniga faʻasaienisi e iloa ai pe a EMS e mafua mai i le 5-HTP, o se faʻaleagaina, poʻo seisi vaega. Seia vagana o sili atu iloa, 5-HTP tatau ona faʻaaoga ma le faʻaeteete.

O isi aʻafiaga ono o le 5-HTP e aofia ai le tiga o le fatu, tiga o le manava, niniva, puaʻi, manava, fia moe, faafitauli tau feusuaiga, ma maso maso.

5-HTP o E L MAFAI ONA FUA pe a ave e le gutu i inumaga tetele. O inumaga mai le 6-10 kalama i aso uma na fesoʻotaʻi ma matuia manava faʻafitauli ma maso maso.

Lapataiga faʻapitoa & lapataʻiga:

Maitaga ma susu-fafagaina: E le lava faʻamatalaga faʻatuatuaina e iloa ai pe a fai o le 5-HTP e saogalemu e faʻaaoga pe a maʻito pe fafagaina susu. Tumau i le itu saogalemu ma aloese mai le faʻaaogaina.

Tamaiti: 5-HTP o MAFAI ONA SAFIA pe a fai e le gutu talafeagai. O inumaga e oʻo atu i le 5 mg / kg i aso uma na faʻaaoga saogalemu mo le oʻo atu i le 3 tausaga i pepe ma tamaiti e oʻo atu i le 12-tausaga le matua. E pei foi o tagata matutua, e iai foi le popolega e uiga i le ono iai le eosinophilia-myalgia syndrome (EMS) i tamaiti, o se tulaga tuga e aofia ai le ogaoga o le maso (myalgia) ma toto le masani ai (eosinophilia).

Taotoga: 5-HTP mafai ona aʻafia se faiʻai vailaʻau ua taʻua o le serotonin. Nisi vailaʻau faʻataʻitaʻia i le taimi o taotoga mafai foi ona aʻafia serotonin. O le inuina o le 5-HTP ae le i faia se taotoga e ono mafua ai le tele o le serotonin i le faiʻai ma mafai ai ona oʻo i ni aafiaga ogaoga e aofia ai ma le fatu fatu, tete, ma le popole. Taʻu i tagata mamaʻi e taofi le toe inu 5-HTP a itiiti mai 2 vaiaso ae leʻi faia le taotoga.

Sili

Aua le avea lenei tuʻufaʻatasiga.

Vailaau mo le faʻanoanoa (MAOI)

5-HTP faʻateleina se vailaʻau i le faiʻai taʻua o le serotonin. O nisi vailaʻau na faʻaaogaina mo le faʻanoanoa e faʻateleina ai foi le serotonin. Aveina 5-HTP ma nei vailaʻau faʻaogaina mo le faʻanoanoa atonu e faʻateleina ai le serotonin. O lenei mea e ono mafua ai aʻafiaga matuia e aofia ai le tiga o le ulu, faʻafitauli o le fatu, tetete, le mautonu, ma le popole.

O nisi o nei vailaʻau e faʻaaoga mo le faʻanoanoa e aofia ai le phenelzine (Nardil), tranylcypromine (Parnate), ma isi.

Feololo

Faʻaeteete i lenei tuʻufaʻatasiga.

Carbidopa (Lodosyn)

5-HTP mafai ona aʻafia le faiʻai. Carbidopa (Lodosyn) e mafai foi ona aʻafia ai le faiʻai. O le aveina o le 5-HTP faʻatasi ai ma le carbidopa e mafai ona faʻateleina ai le aʻafia o aʻafiaga ogaoga e aofia ai le vave ona tautala, atuatuvale, faʻasauā, ma isi.

Vailaau faʻamalieina (CNS depressants)

5-HTP ono mafua ai le fia moe ma le fia moe. O vailaʻau e mafua ai le fia moe ua taʻua o ni vailaau faʻamalieina. Aveina 5-HTP faʻatasi ai ma vailaʻau faʻafofilemu e ono mafua ai tele moe.

O ni vailaʻau faʻamalieina e aofia ai clonazepam (Klonopin), lorazepam (Ativan), phenobarbital (Donnatal), zolpidem (Ambien), ma isi.

Vailaau serotonergic

5-HTP mafai faʻateleina se vailaʻau i le faiʻai valaʻauina serotonin. O nisi vailaʻau faʻateleina foi serotonin. Aveina 5-HTP faʻatasi ma nei vailaʻau ono faʻateleina serotonin tele. Lenei mafai mafua mafua 'aʻafiaga leaga aofia ai matuitui tiga ulu, fatu faʻafitauli, gatete, le mautonu, ma le popole.

O nisi o nei vailaʻau e aofia ai le fluoxetine (Prozac), paroxetine (Paxil), sertraline (Zoloft), amitriptyline (Elavil), clomipramine (Anafranil), imipramine (Tofranil), sumatriptan (Imitrex), zolmitriptan (Zomig), rizatran methadone (Dolophine), tramadol (Ultram), ma le tele o isi.

Laʻau ma mea faʻaopopo ma mea faʻafilemu

5-HTP mafai ona mafua ai le moe pe moe. Faʻaaogaina faʻatasi ma isi laʻau ma fualaʻau e tutusa a latou aʻafiaga ono mafua ai tele le moe. O nisi o nei vailaʻau ma mea faʻapipiʻi e aofia ai le calamus, California poppy, catnip, hops, Jamaican dogwood, kava, St. John's wort, skullcap, valerian, yerba mansa, ma isi.

Laʻau ma mea faʻaopopo ma meatotino serotonergic

5-HTP faʻateleina le faiʻai vailaʻau taʻua serotonin. Aveina 5-HTP faʻatasi ai ma isi laʻau ma mea faʻaopopo e faʻatele ai le serotonin ono mafua ai le tele o le serotonin ma mafua ai aʻafiaga e aofia ai faʻafitauli o le fatu, gatete ma le popole. O isi fualaʻau ma faʻalautelega e faʻateleina ai le maualuga o le serotonin e aofia ai le pepe pepe ole laau ole Hawaii, L-tryptophan, S-adenosylmethionine (SAMe), ma le St. John's wort.

E leai ni fesoʻotaʻiga iloa ma meaʻai.

O vailaʻau nei sa suʻesuʻeina i suʻesuʻega faasaienisi. MATUTUA

E SAUNIU:

• Mo faʻanoanoaga: Sili ona masani ai, 150-800 mg i aso uma e ave mo le 2-6 vaiaso. O nei tui e masani ona vaevaeina ma faʻatautaia e pei o le 50 mg i le 100 mg tolu taimi i le aso. O isi taimi o le fualaʻau e amata maualalo ma faʻateleina le faʻaopopoina i vaiaso uma 1-2 seʻia oʻo i le faʻatulagaina o fualaʻau. Faʻaititia, e maualuga tui e faʻaaogaina. I se tasi suʻesuʻega, o le fualaʻau o loʻo faʻaauau pea faʻateleina i le 3 kalama i le aso.

2-Amino-3- (5-Hydroxy-1H-Indol-3-yl) Oona Propanoic, 5 Hydroxy-Tryptophan, 5 Hydroxy-Tryptophane, 5-Hydroxytr Egyptophan, 5-Hydroxytr Egyptophane, 5-Hydroxy L-Tryptophan, 5-Hydroxy L-Tryptophane, 5-Hydroxy Tryptophan, 5-L-Hydroxytr Egyptophan, L-5 HTP, L-5-Hydroxytr Egyptophan, L-5-Hydroxytr Egyptophane, Oxitriptan.

Ina ia aoao atili e uiga i le auala na tusia ai lenei tusitusiga, faʻamolemole vaʻai i le Natura Faʻafomaʻi Maea Faʻamatalaga metotia

1. Meloni M, Puligheddu M, Sanna F, et al. Malosiaga ma le saogalemu o le 5-Hydroxytr Egyptophan i luga o le levodopa-faʻaosoina afi faʻafitauli i Parkinson faamaʻi: O se uluaʻi sailiiliga. J Neurol Sci. 2020; 415: 116869. Vaʻai faʻamatala.
2. Yousefzadeh F, Sahebolzamani E, Sadri A, et al. 5-Hydroxytr Egyptophan o adjuvant togafitiga i togafitiga o feololo i le ogaoga mataga-o le le atoatoa le atoatoa: o se lua-tauaso randomized faamasinoga ma placebo pulea. Int Clin Psychopharmacol. 2020; 35: 254-262. Vaʻai faʻamatala.
3. Javelle F, Lampit A, Bloch W, Häussermann P, Johnson SL, Zimmer P. Aafiaga o le 5-hydroxytr Egyptophan i luga o ituaiga eseese o le atuatuvale: o se iloiloga faʻavasega ma meta-auiliiliga. Nutr Rev 2020; 78: 77-88. Vaʻai faʻamatala.
4. Meloni M, Puligheddu M, Carta M, Cannas A, Figorilli M, Defazio G. Malosiaga ma le saogalemu o le 5-hydroxytr Egyptophan i luga o le atuatuvale ma le le fiafia i le faʻamaʻi a Parkinson: o se uluaʻi sailiiliga. Eur J Neurol 2020; 27: 779-786. Vaʻai faʻamatala.
5. Isalaelu N, Del Colle A, Li Z, et al. Aʻafiaga o Serotonin ma Lemu-Faʻamalolo 5-Hydroxytr Egyptophan luga Gastrointestinal Faʻaaoga i se Isumu Faʻataʻitaʻiga o le Loloto Faʻanoanoa. Gastroenterology. 2019; 157: 507-521.e4. Vaʻai faʻamatala.
6. Michelson D, Itulau SW, Casey R, et al. O le eosinophilia-myaligia syndrome e fesoʻotaʻi ma le maʻi e fesoʻotaʻi ma le aafia i l-5-hydroxytr Egyptophan. J Rheumatol 1994; 21: 2261-5. Vaʻai faʻamatala.
7. Lemaire PA, Adosraku RK. O se metotia HPLC mo le suʻesuʻeina saʻo o le serotonin precursor, 5-hydroxytrophan, i fatu o Griffonia simplicifolia. Phytochem Anal 2002; 13: 333-7.
8. Rondanelli M, Opizzi A, Faliva M, Bucci M, Perna S. Faʻafesoʻotaʻiga i le va o le faʻaaogaina o le 5-hydroxytr Egyptophan mai le tuʻufaʻatasia o meaʻai, e ala i le Griffonia simplicifolia otoʻoto, ma le aʻafiaga i le faʻamalieina i le sili atu fafine mamafa pe a maeʻa tuʻuina o le spray spray. Eat Weight Disord 2012; 17: e22-8. Vaʻai faʻamatala.
9. Pardo JV. Mania mulimuli ane faʻaopopoina o hydroxytr Egyptophan i le monoamine oxidase inhibitor. Gen Hosp Psychiatry 2012; 34: 102.e13-4.
10. Chen D, Liu Y, He W, Wang H, Wang Z. Neurotransmitter-precursor-supplement intervensors mo detoxified heroin addicts. J Huazhong Univ Sci Technolog Med Sci 2012; 32: 422-7.
11. Gendle MH, Young EL, Romano AC. Aʻafiaga o le tautala 5-hydroxytr Egyptophan i luga o le faʻatulagaina fuafuaina gaioiga: malamalamaʻaga i mafai dopamine / serotonin fegalegaleaiga i le forebrain. Hum Psychopharmacol 2013; 28: 270-3.
12. Fonotaga a le Komiti Faufautua Faʻafesoʻotaʻi o Fale Talavai a U.S.
13. U.S. Taumafa ma Vailaau Faʻafoeina. Tamaititi matuaoti Tofia igoa ma faʻamaoniga. Avanoa i le: www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm (ulufale i le 8/20/2015).
14. Das YT, Bagchi M, Bagchi D, Preuss HG. Saogalēmū o le 5-hydroxy-L-tryptophan. Toxicol Lett 2004; 150: 111-22. Vaʻai faʻamatala.
15. Weise P, Koch R, Shaw KN, Rosenfeld MJ. Le faʻaaogaina ole 5-HTP ile togafitia ole Down's syndrome. Pediatrics 1974; 54165-8. Vaʻai faʻamatala.
16. Bazelon M, Paine RS, Cowie VA, et al. Toe fesuiaiga o le hyponia i tamaiti laiti ma Down's syndrome e ala i le faʻatautaia o le 5-hydroxytr Egyptophan. Lancet 1967; 1: 1130-3. Vaʻai faʻamatala.
17. Sano I. Togafitiga o le faʻanoanoaga ma L-5-hydroxytr Egyptophan (L-5-HTP). Psychiatria et Neurologia Japonicas 1972; 74: 584.
18. Klein P, Lees A, ma Stern G. Taunuʻuga o le tumau 5-hydroxytr Egyptophan i le parkinsonian le mautonu o le savali ma paleni ma isi neurological faʻaletonu. Adv Neurol 1986; 45: 603-604.
19. VanPraag, H. M. ma Korf, J. 5-Hydroxytr Egyptophan o le antidepressant: O le valoʻaga taua o le suʻega probenecid. Psychopharmacol.Fanau. 1972; 8: 34-35.
20. Sicuteri F. 5-hydroxytr Egyptophan i le faʻataʻitaʻiga o migraine. Fesoʻotaʻiga i Sailiga Faʻafomaʻi Faʻapitoa 1972; 4: 213-218
21. Rosano Burgio, F., Borgatti, R., Scarabello, E., ma Lanzi, G. Uiga tiga i tamaiti ma talavou. Taualumaga o le Muamua Faʻavaomalo Symposium i luga o le Ulu o tamaiti ma Adolecents. 1989; 339-47.
22. Mathew NT. 5-hydroxytr Egyptophan i le prophylaxis o migraine: o se faʻalua-tauaso suʻesuʻega. Uiga o ulu 1978; 18: 111.
23. De Benedittis G, Massei R. 5-HT muamua i migraine prophylaxis: o se lua-tauaso kolosi-i luga o suʻesuʻega ma L-5-hydroxytr Egyptophan. Clin J Pain 1986; 2: 123-129.
24. Wyatt, R. J., Vaughan, T., Kaplan, J., Galanter, M., ma Green, R. 5-Hydroxytr Egyptophan ma schizophrenia masani. I: Barchas J ma Usdin E. Serotonin ma Amio. Niu Ioka: Acedemic Press; 1973.
25. Brodie HKH, Sack R, ma Siever L. Suesuega faʻapitoa i le L-5-hydroxytr Egyptophan i le loto popole. I: Barchas J ma Usdin E. Serotonin ma amioga. Niu Ioka: Academic Press; 1973.
26. Auffret, M., Comte, H., ma Bene, J. Eosinophilia-myalgia syndrome na faʻaosoina e le L-5 hydroxytr Egyptophane: tusa o le tolu mataupu. Fund Clinacacol 2013; Faʻaopopo 1: pepa lautele P2-204.
27. Cangiano C, Laviano A, Del Ben M, et al. Aʻafiaga o le gutu 5-hydroxy-tryptophan i le malosi faʻaaogaina ma macronutrient filifilia i le leai-inisalini tagata gasegase maʻisuka. Int J Obes Relat Metab Disord 1998; 22: 648-54. Vaʻai faʻamatala.
28. Ju, C. Y. ma Tsai, C. T. Serotonergic auala na aofia ai i le taofiofia o le fafagaina e le 5-HTP i isumu. Chin J Physiol 1995; 38: 235-240. Vaʻai faʻamatala.
29. Pranzatelli, M. R., Tate, E., Galvan, I., ma Wheeler, A. O le faʻatonutonuina faʻataʻitaʻi o le 5-hydroxy-L-tryptophan mo ataxia i le alualu i luma myoclonus epilepsy. Clin Neurol.Neurosurg. 1996; 98: 161-164. Vaʻai faʻamatala.
30. Frith, C. D., Johnston, E. C., Joseph, M. H., Powell, R. J., ma Watts, R. W. Faʻalua-tauaso faʻataʻitaʻi faʻataʻitaʻi falemaʻi o le 5-hydroxytr Egyptophan i se mataupu o le Lesch- Nyhan syndrome. J Neurol Neurosurg. Tomai Faʻapitoa 1976; 39: 656-662. Vaʻai faʻamatala.
31. Bastard, J., Truelle, J. L., ma Emile, J. [Le aoga o le 5 hydroxy-tryptophan i le faʻamaʻi a Parkinson]. Nouv Presse Med 9-11-1976; 5: 1836-1837. Vaʻai faʻamatala.
32. Trouillas P, Serratrice G, Laplane D, et al. Levorotatory form of 5-hydroxytr Egyptophan i Friedreich's ataxia. Faʻaiuga o le lua-tauaso fualaʻau-placebo felagolagomai suʻesuʻega. Arch Neurol 1995; 52: 456-60. Vaʻai faʻamatala.
33. Wessel K, H germdörfer J, Deger K, et al. Suesuega crossover lua-tauaso ma levorotatory ituaiga o hydroxytr Egyptophan i tagata mamaʻi ma degenerative cerebellar faamaʻi. Arch Neurol 1995; 52: 451-5. Vaʻai faʻamatala.
34. Alino, J. J., Gutierrez, J. L., ma Iglesias, M. L. 5-Hydroxytr Egyptophan (5-HTP) ma le MAOI (nialamide) i le togafitia o faʻanoanoaga. O se lua-tauaso pulea faʻatonutonuina. Int Pharmacopsychiatry 1976; 11: 8-15. Vaʻai faʻamatala.
35. Pranzatelli, M. R., Tate, E., Huang, Y., Haas, R. H., Bodensteiner, J., Ashwal, S., ma Franz, D. Neuropharmacology o le alualu i luma myoclonus epilepsy: tali i le 5- hydroxy-L-tryptophan. Epilepsia 1995; 36: 783-791. Vaʻai faʻamatala.
36. Thomson, J., Rankin, H., Ashcroft, GW, Yates, CM, McQueen, JK, ma Cummings, SW O le togafitia o le faʻanoanoa i le masani masani: o se faʻatusatusaga o L-tryptophan, amitriptyline, ma le tuʻufaʻatasia o L-tryptophan ma amitriptyline ma placebo. Psychol Med 1982; 12: 741-751. Vaʻai faʻamatala.
37. Trouillas, P., Garde, A., Robert, JM, Renaud, B., Adeleine, P., Bard, J., ma Brudon, F. [Faʻafitauli o le cerebellar syndrome i lalo o le taimi umi pulega o le 5-HTP poʻo o le tuʻufaʻatasia o 5-HTP ma benserazide. 26 mataupu faanumeraina ma togafitia faʻaaogaina metotia komepiuta]. Rev Neurol. (Paris) 1982; 138: 415-435. Vaʻai faʻamatala.
38. Thal, L. J., Sharpless, N. S., Wolfson, L., ma Katzman, R. Togafitiga o le myoclonus ma L-5-hydroxytr Egyptophan ma carbidopa: togafitiga, electrophysiological, ma biochemical matauina. Ann Neurol 1980; 7: 570-576. Vaʻai faʻamatala.
39. van Hiele LJ. l-5-Hydroxytr Egyptophan i faʻanoanoaga: o le muamua sui togafitiga i le mafaufau? Le togafitia o 99 fafo-tagata mamaʻi ma 'togafitiga-teteʻe' atuatuvale. Neuropsychobiology 1980; 6: 230-40. Vaʻai faʻamatala.
40. Magnussen, I.ma Nielsen-Kudsk, F. Bioavailability ma isi vailaʻau e fesoʻotaʻi i le tamaloa ma le tuʻuina atu o le L-5-hydroxytr Egyptophan i le setete tumau Acta Pharmacol Toxicol. (Copenh) 1980; 46: 257-262. Vaʻai faʻamatala.
41. Trouillas, P., Garde, A., Robert, J. M., ma Adeleine, P. [Regression o tagata cerebellar ataxia i lalo o le umi pulega o le 5-hydroxytr Egyptophan]. CR Vaʻai Acad Sci III 1-5-1981; 292: 119-122. Vaʻai faʻamatala.
42. Pueschel SM, Reed RB, Cronk CE, Goldstein BI. 5-hydroxytr Egyptophan ma pyridoxine. O latou aʻafiaga i tamaiti laiti e maua i le Down's syndrome. Am J Dis Child 1980; 134: 838-44. Vaʻai faʻamatala.
43. Longo G, Rudoi I, Iannuccelli M, Strinati R, Panizon F. [Togafitiga o le tiga o le ulu i tausaga tuputupu aʻe ma L-5-HTP (kolosi luga faʻalua-tauaso suʻesuʻega ma le placebo)]. Pediatr Med Chir 1984; 6: 241-5. Vaʻai faʻamatala.
44. Bono, G., Micieli, G., Sances, G., Calvani, M., ma Nappi, G. L-5HTP togafitiga i ulu muamua ulu: o se taumafaiga i le faʻailoaina faʻapitoa o gasegase tali atu. Cephalalgia 1984; 4: 159-165. Vaʻai faʻamatala.
45. Quadbeck, H., Lehmann, E., ma Tegeler, J. Faʻatusatusaga o le antidepressant gaioiga o le tryptophan, tryptophan / 5- hydroxytr Egyptophan tuʻufaʻatasia ma filifilia. Neuropsychobiology 1984; 11: 111-115. Vaʻai faʻamatala.
46. van Praag, H. M. I le sailiga o le auala o gaioiga a antidepressants: 5-HTP / tyrosine mixtures i le faʻanoanoaga. Adv Biochem Psychopharmacol. 1984; 39: 301-314. Vaʻai faʻamatala.
47. Trouillas P.Regression o cerebellar syndrome ma le umi o le pulega o le 5-HTP poʻo le tuʻufaʻatasia o 5-HTP-benserazide: 21 mataupu faʻatasi ai ma faʻailoga tetele na faʻatautaia e le komipiuta. Ital J Neurol Sci 1984; 5: 253-266. Vaʻai faʻamatala.
48. van Praag, H. M. ma de Haan, S. Chemoprophylaxis o faʻanoanoaga. O se taumafaiga e faʻatusatusa le lithium ma le 5- hydroxytr Egyptophan. Acta Psychiatr. Faʻailoga Faʻapitoa 1981; 290: 191-201. Vaʻai faʻamatala.
49. van Praag, H. ma de Hann, S. Faʻanoanoaga vaivai ma 5-hydroxytr Egyptophan prophylaxis. Psychiatry Res. 1980; 3: 75-83. Vaʻai faʻamatala.
50. Soulairac, A. [Hypnotic gaioiga o mecloqualone. Faʻatusatusaga ma placebo aʻafiaga ma secobarbital]. Presse Med 4-10-1971; 79: 817-818. Vaʻai faʻamatala.
51. Chase, T. N., Ng, L. K., ma Watanabe, A. M. Parkinson's faamaʻi. Fesuiaiga e 5-hydroxytr Egyptophan. Neurology 1972; 22: 479-484. Vaʻai faʻamatala.
52. Wyatt, R. J., Vaughan, T., Galanter, M., Kaplan, J., ma Green, R. Suiga amioga o gasegase schizophrenic masani na maua L-5- hydroxytr Egyptophan. Saienisi 9-22-1972; 177: 1124-1126. Vaʻai faʻamatala.
53. van Praag HM, Korf J, Dols LC, Schut T. O se pailate suʻesuʻega o le valoʻaga taua o le suʻega probenecid i le faʻaogaina o le 5-hydroxytr Egyptophan o le antidepressant. Psychopharmacologia 1972; 25: 14-21. Vaʻai faʻamatala.
54. Zarcone, V., Kales, A., Scharf, M., Tan, T. L., Simmons, J. Q., ma Dement, W. C. Faateleina le inuina o le tautala i le 5-hydroxytr Egyptophan. O le aʻafiaga o amioga ma le moe i ni tamaiti se toʻalua. Arch Gen Psychiatry 1973; 28: 843-846. Vaʻai faʻamatala.
55. Chadwick, D., Hallett, M., Harris, R., Jenner, P., Reynolds, EH, ma Marsden, CD Clinical, biochemical, ma foliga faʻapitoa e faʻaeseese ai le myoclonus tali atu i le 5-hydroxytr Egyptophan, tryptophan ma le monoamine oxidase inhibitor, ma clonazepam. Brain 1977; 100: 455-487. Vaʻai faʻamatala.
56. Van Woert, M. H., Rosenbaum, D., Howieson, J., ma Bowers, M. B., Jr. Togafitiga umi o myoclonus ma isi gasegase o le neurologic ma L-5- hydroxytr Egyptophan ma carbidopa. N Engl J Med 1-13-1977; 296: 70-75. Vaʻai faʻamatala.
57. Nolen WA, van de Putte JJ, Dijken WA, Kamp JS. L-5HTP i le faʻanoanoaga e teteʻe atu i le toe aveina o tagata faʻalavelave. O se matala faʻatusatusa suʻesuʻega ma tranylcypromine. Br J Psychiatry 1985; 147: 16-22. Vaʻai faʻamatala.
58. De Benedittis G, Massei R. Serotonin muamua i tiga masani ulu ulu. O se lua-tauaso kolosi-i luga o suʻesuʻega ma L-5-hydroxytr Egyptophan vs. placebo. J Neurosurg Sci 1985; 29: 239-48. Vaʻai faʻamatala.
59. Titus F, Dávalos A, Alom J, Codina A. 5-Hydroxytr Egyptophan versus methysergide i le prophylaxis o migraine. Faʻataʻitaʻiga faʻafomaʻi falemaʻi. Eur Neurol 1986; 25: 327-9. Vaʻai faʻamatala.
60. Santucci M, Cortelli P, Rossi PG, Baruzzi A, Sacquegna T. L-5-hydroxytr Egyptophan versus placebo i tamaiti laiti migraine prophylaxis: o se lua-tauaso crossover suesuega. Cephalalgia 1986; 6: 155-7. Vaʻai faʻamatala.
61. Irwin, M. R., Marder, S. R., Fuentenebro, F., ma Yuwiler, A. L-5-hydroxytr Egyptophan faʻamalieina lelei psychotic auga faʻamalosia e D-amphetamine. Psychiatry Res. 1987; 22: 283-289. Vaʻai faʻamatala.
62. Angst J, Woggon B, Schoepf J. O le togafitia o le faʻanoanoaga ma L-5-hydroxytr Egyptophan versus imipramine. Iʻuga o lua matala ma tasi faʻalua-tauaso suesuega. Faʻapitoa Psychiatr Nervenkr 1977; 224: 175-86. Vaʻai faʻamatala.
63. Kahn RS, Westenberg HG, Verhoeven WM, et al. Aʻafiaga o le serotonin precursor ma uptake inhibitor i faʻalavelave popole; se faʻalua-tauaso faʻatusatusaga o le 5-hydroxytr Egyptophan, clomipramine ma le placebo. Int Clin Psychopharmacol 1987; 21: 33-45. Vaʻai faʻamatala.
64. De Giorgis G, Miletto R, Iannuccelli M, Camuffo M, Scerni S. Headache e fesoʻotaʻi ma le moe i tamaiti: o le psychodiagnostic iloiloina ma faʻatonutonu suʻesuʻe falemaʻi - L-5-HTP versus placebo. Fualaʻau Exp Clin Res 1987; 13: 425-33. Vaʻai faʻamatala.
65. Zmilacher, K., Battegay, R., ma Gastpar, M. L-5-hydroxytr Egyptophan na o ia ma faatasi ai ma le peripheral decarboxylase inhibitor i le togafitia o le faʻanoanoa. Neuropsychobiology 1988; 20: 28-35. Vaʻai faʻamatala.
66. Nolen, W. A., van de Putte, J. J., Dijken, W. A., Kamp, J. S., Blansjaar, B. A., Kramer, H. J., ma Haffmans, J. Togafitiga togafiti i le atuatuvale. II. MAO taofi i le faʻanoanoaga e teteʻe atu i vailaʻau o le cyclic antidepressants: lua faʻatonutonu suʻesuʻeina suʻesuʻega ma le tranylcypromine ma le L-5-hydroxytr Egyptophan ma le nomifensine. Acta Psychiatr.Scand 1988; 78: 676-683. Vaʻai faʻamatala.
67. Kaneko M, Kumashiro H, Takahashi Y, Hoshino Y. L-5HTP togafitiga ma le serum 5-HT maualuga i le maeʻa ai o le L-5-HTP uta i tagata mamaʻi faʻanoanoa. Neuropsychobiology 1979; 5: 232-40. Vaʻai faʻamatala.
68. Rousseau JJ. Aʻafiaga o le levo-5-hydroxytr Egyptophan-dihydroergocristine tuʻufaʻatasia luga faʻanoanoaga ma neuropsychic gaioiga: a lua-tauaso placebo-faʻatautaia falemaʻi faʻataʻitaʻi i tagata matutua gasegase. Clin Ther 1987; 9: 267-72. Vaʻai faʻamatala.
69. Anders, T. F., Cann, H. M., Ciaranello, R. D., Barchas, J. D., ma Berger, P. A. O isi faʻamatalaga e uiga i le faʻaaogaina o le 5-hydroxytr Egyptophan i se tamaititi e maua i le Lesch-Nyhan syndrome. Neuropadiatrie 1978; 9: 157-166. Vaʻai faʻamatala.
70. Ceci F, Cangiano C, Cairella M, et al. O aʻafiaga o le tautala ile 5-hydroxytryptophan ile faʻatagaina o amioga ile tamaʻitaʻi matutua o fafine matutua. J Neural Transm 1989; 76: 109-17. Vaʻai faʻamatala.
71. Jangid P, Malik P, Singh P, Sharma M, Gulia AK. Suʻesuʻega faʻatusatusa o le aoga o l-5-hydroxytr Egyptophan ma le fluoxetine i tagata mamaʻi o loʻo iai ma le faʻafitauli muamua. Asia J Psychiatr 2013; 6: 29-34. Vaʻai faʻamatala.
72. Zarcone, V. P., Jr. ma Hoddes, E. Aʻafiaga o le 5-hydroxytr Egyptophan i luga o le vaevaega o le moe REM i tagata inu ava malosi. Am J Psychiatry 1975; 132: 74-76. Vaʻai faʻamatala.
73. Opladen, T., Hoffmann, G. F., ma Blau, N. O se suʻesuʻega faavaomalo o tagata mamaʻi ma tetrahydrobiopterin faaletonu o loʻo faʻaalia ma le hyperphenylalaninaemia. J Inherit.Metab Dis 2012; 35: 963-973. Vaʻai faʻamatala.
74. Baraldi, S., Hepgul, N., Mondelli, V., ma Pariante, C. M. Faʻailogaina togafitiga o le interferon-alpha-induced depression i le hepatitis C: o se faʻavasega iloiloga. J Clin Psychopharmacol. 2012; 32: 531-543. Vaʻai faʻamatala.
75. Pan, L., McKain, BW, Madan-Khetarpal, S., Mcguire, M., Diler, RS, Perel, JM, Vockley, J., ma Brent, DA GTP-cyclohydrolase le lava e tali atu i le sapropterin ma le 5-HTP supplementation : mapusaga o togafitiga-faʻafitauli faʻanoanoa ma amioga pule i le ola. BMJ Mataupu.Rep. 2011; 2011 Vaʻai faʻamatala.
76. Friedman, J., Roze, E., Abdenur, JE, Chang, R., Gasperini, S., Saletti, V., Wali, GM, Eiroa, H., Neville, B., Felice, A., Parascandalo, R., Zafeiriou, DI, Arrabal-Fernandez, L., Dill, P., Eichler, FS, Echenne, B., Gutierrez-Solana, LG, Hoffmann, GF, Hyland, K., Kusmierska, K., Tijssen, MA, Lutz, T., Mazzuca, M., Penzien, J., Poll-The BT, Sykut-Cegielska, J., Szymanska, K., Thony, B., ma Blau, N. Sepiapterin faʻaletonu le toe maua: o se fofo faʻataʻitaʻi o le supa supa. Ann Neurol. 2012; 71: 520-530. Vaʻai faʻamatala.
77. Jukic T, Rojc B, Boben-Bardutzky D, Hafner M, Ihan A. O le faʻaaogaina o se faʻaopoopoga o meaʻai ma le D-phenylalanine, L-glutamine ma le L-5-hydroxytriptophan i le faʻaitiitia o faʻamalologa o le toʻaga o le 'ava malosi. Coll Antropol 2011; 35: 1225-30. Vaʻai faʻamatala.
78. Sarris, J. Clinical depression: o se faʻamaoniga-faʻavae integrative tuʻufaʻatasi vailaʻau togafitiga togafitiga. Suʻesuʻega o le soifua maloloina Med. 2011; 17: 26-37. Vaʻai faʻamatala.
79. Dill, P., Wagner, M., Somerville, A., Thony, B., Blau, N., ma Weber, P. Tamaititi neurology: paroxysmal malo, vaai i luga, ma hyponia: uiga taua o sepiapterin reductase le atoatoa. Neurology 1-31-2012; 78: e29-e32. Vaʻai faʻamatala.
80. Horvath, GA, Selby, K., Poskitt, K., Hyland, K., Waters, PJ, Coulter-Mackie, M., ma Stockler-Ipsiroglu, SG Hemiplegic migraine, faoa faamalosi, alualu i luma spastic paraparesis, lagona le lelei, ma le koma i uso ma maualalo sisitema serotonin. Cephalalgia 2011; 31: 1580-1586. Vaʻai faʻamatala.
81. Morrison, K. E. Aofaʻi-genome faʻasologa faʻamatalaina togafitiga: faʻapitoa vailaʻau faia se isi laʻasaga i luma. Clin Chem 2011; 57: 1638-1640. Vaʻai faʻamatala.
82. Bainbridge, MN, Wiszniewski, W., Murdock, DR, Friedman, J., Gonzaga-Jauregui, C., Newsham, I., Reid, JG, Fink, JK, Morgan, MB, Gingras, MC, Muzny, DM, Hoang, LD, Yousaf, S., Lupski, JR, ma Gibbs, RA Atoa-genome faʻasologa mo sili lelei faʻatautaia tagata gasegase. Faʻaliliu Upu Faʻafitauli. Vaʻai faʻamatala.
83. den Boer JA, Westenberg HG. Amioga, neuroendocrine, ma aafiaga biochemical o le 5-hydroxytr Egyptophan pulega i le popolevalevale. Psychiatry Res 1990; 31: 267-78. Vaʻai faʻamatala.
84. Adamsen, D., Meili, D., Blau, N., Thony, B., ma Ramaekers, V. Autism e fesoʻotaʻi ma le maualalo o le 5-hydroxyindolacetic acid i le CSF ma le heterozygous SLC6A4 gene Gly56Ala faʻatasi ai ma le 5-HTTLPR L / L tagata faʻalauiloa ituaiga. . Mol.Genet.Metab 2011; 102: 368-373. Vaʻai faʻamatala.
85. Cross, D. R., Kellermann, G., McKenzie, L. B., Purvis, K. B., Hill, G. J., ma Huisman, H.O se vailaʻau faʻasolosolo o le amino acid faʻasolosolo faʻapitoa ma tamaiti amio lelei e ono aʻafia. Tamaiti Fanau Soifua Maloloina Dev. 2011; 37: 671-678. Vaʻai faʻamatala.
86. Gendle, M. H. ma Golding, A. C. Tautala tuʻufaʻatasiga o le 5-hydroxytr Egyptophan (5-HTP) faʻaletonu filifiliga faia i lalo o le le mautonu ae le o lamatia: faʻamaoniga mai le Iowa Taaloga Galue. Hum Psychopharmacol. 2010; 25: 491-499. Vaʻai faʻamatala.
87. Iovieno, N., Dalton, E. D., Fava, M., ma Mischoulon, D. Second-tier natural antidepressants: iloiloga ma faitioga. J Aafia. Disorda. 2011; 130: 343-357. Vaʻai faʻamatala.
88. Leu-Semenescu, S., Arnulf, I., Decaix, C., Moussa, F., Clot, F., Boniol, C., Touitou, Y., Levy, R., Vidailhet, M., ma Roze, E. Moe ma fati taunuuga o le genetically faaosoina leiloa o serotonin. Moe 3-1-2010; 33: 307-314. Vaʻai faʻamatala.
89. Freedman RR. Togafitiga o menopausal vevela susulu ma 5-hydroxytryptophan. Maturitas 2010; 65: 383-5. Vaʻai faʻamatala.
90. Vaiaso, B. S. Faʻatulagaina o meaʻai faʻaopopo ma vailaʻau oona mo le malologa ma le faʻalavelave gaioiga: Relarian. Med Sci Monit. 2009; 15: RA256-RA262. Vaʻai faʻamatala.
91. Rondanelli M, Klersy C, Iadarola P, et al. Satiety ma amino-acid faʻamatalaga i fafine sili atu le mamafa i le maeʻa ai o se togafitiga fou e faʻaaoga ai le natura laʻau faʻasolosolo sublingual spray formulate. Int J Obes (Lond) 2009; 33: 1174-1182. Vaʻai faʻamatala.
92. Maissen CP, Ludin HP. [Faʻatusatusaga o le aʻafiaga o le 5-hydroxytr Egyptophan ma le propranolol i le va o togafitiga o migraine]. Schweiz Med Wochenschr 1991; 121: 1585-90. Vaʻai faʻamatala.
93. Shell W, Bullias D, Charuvastra E, et al. O se faʻataʻitaʻiga, faʻataʻitaʻia-faʻataʻitaʻia le faʻataʻitaʻia o se sauniuniga amino acid i taimi ma lelei o le moe. Am J Ther 2010; 17: 133-9. Vaʻai faʻamatala.
94. Trujillo-Martin, M. M., Serrano-Aguilar, P., Monton-Alvarez, F., ma Carrillo-Fumero, R. Lelei ma le saogalemu o togafitiga mo ataxias faʻaleagaina: o se faʻavasega iloiloga. Faʻaleagaina. 6-15-2009; 24: 1111-1124. Vaʻai faʻamatala.
95. Rothman, R. B. Togafitiga o le puta tele ma le "tuʻufaʻatasia" vailaʻau. Am J Ther 2010; 17: 596-603. Vaʻai faʻamatala.
96. Chae, HS, Kang, OH, Choi, JG, Oh, YC, Lee, YS, Jang, HJ, Kim, JH, Park, H., Jung, KY, Sohn, DH, ma Kwon, DY 5-hydroxytr Egyptophan gaioiga i o le mitogen-activated protein kinase extracellular-signal regulated protein kinase pathway e faʻatonu ai le cyclooxygenase-2 ma le faʻaaogaina o le nitric oxide synthase faʻaaliga i RAW 264.7 sela. Biol Pharm Bull 2009; 32: 553-557. Vaʻai faʻamatala.
97. Hendricks, E. J., Rothman, R. B., ma Greenway, F. L. Faʻafefea ona faʻaaoga e fomaʻi faʻapitoa i vailaʻau oona ia vailaʻau e togafitia ai le lapoʻa. Lapoʻa. (Silver. Spring) 2009; 17: 1730-1735. Vaʻai faʻamatala.
98. Longo, N. Faʻalavelave o le biopterin metabolism. J Inherit.Metab Dis 2009; 32: 333-342. Vaʻai faʻamatala.
99. Pons, R. O le phenotypic fusi o faʻamaʻi neurotransmitter tamaiti ma parkinsonism pepe. J Inherit.Metab Dis 2009; 32: 321-332. Vaʻai faʻamatala.
100. Schaefer, M., Winterer, J., Sarkar, R., Uebelhack, R., Franke, L., Heinz, A., ma Friebe, A. Tolu mataupu o le manuia tryptophan faʻaopoopoga poʻo monotherapy o le hepatitis C ma IFNalpha -fesoʻotaʻi faʻaletonu lagona. Psychosomatics 2008; 49: 442-446. Vaʻai faʻamatala.
101. Jacobsen, JP, Nielsen, EO, Hummel, R., Redrobe, JP, Mirza, N., ma Weikop, P. Le le malamalama o isumu NMRI i filifiliga filifilia o le serotonin reuptake i le siʻu faʻataʻitaʻiga suʻega mafai ona suia e le tuʻufaʻatasia ma 5 -hydroxytr Egyptophan. Psychopharmacology (Berl) 2008; 199: 137-150. Vaʻai faʻamatala.
102. Liu, K. M., Liu, T. T., Lee, N. C., Cheng, L. Y., Hsiao, K. J., ma Niu, D. M. Long-term tuliloaina o Taiwanese Saina tagata mamaʻi na togafitia vave mo 6-pyruvoyl-tetrahydropterin synthase le lava. Faʻaputuga Neurol. 2008; 65: 387-392. Vaʻai faʻamatala.
103. Horvath, GA, Stockler-Ipsiroglu, SG, Salvarinova-Zivkovic, R., Lillquist, YP, Connolly, M., Hyland, K., Blau, N., Rupar, T., ma le Vai, PJ Autosomal recessive GTP cyclohydrolase I le lava e aunoa ma le hyperphenylalaninemia: faʻamaoniga o le faʻaauau phenotypic i le va o puleaga ma recessive ituaiga. Mol.Genet.Metab 2008; 94: 127-131. Vaʻai faʻamatala.
104. Morrow, J. D., Vikraman, S., Imeri, L., ma Opp, M. R. Aafiaga o le faʻamalosia o le serotonergic e le 5-hydroxytr Egyptophan i luga o le moe ma le vevela o le tino o C57BL / 6J ma interleukin-6-misia isumu o fualaʻau ma taimi fesoʻotaʻi. Moe 1-1-2008; 31: 21-33. Vaʻai faʻamatala.
105. Meolie, AL, Rosen, C., Keriso, D., Kohrman, M., Gooneratne, N., Aguillard, RN, Fayle, R., Troell, R., Townsend, D., Claman, D., Hoban, T., ma Mahowald, M. Tautala tuʻufaʻatusalia togafitiga mo insomnia: o se iloiloga o oloa ma tapulaʻa faʻamaoniga. J Clin. Moe Med 4-15-2005; 1: 173-187. Vaʻai faʻamatala.
106. Cangiano C, Ceci F, Cairella M, et al. Aʻafiaga o le 5-hydroxytryptophan i luga o le 'ai amioga ma le tausisi i meaʻai talavai i tagata matutua matutua. Adv Exp Med Biol 1991; 294: 591-3. Vaʻai faʻamatala.
107. Petre-Quadens, O. ma De Lee, C. 5-Hydroxytr Egyptophan ma moe i le Down's syndrome. J Neurol Sci 1975; 26: 443-453. Vaʻai faʻamatala.
108. Lesch, K. P., Hoh, A., Disselkamp-Tietze, J., Wiesmann, M., Osterheider, M., ma Schulte, H. M. 5-Hydroxytr Egyptamine1A tali o le tali atu i le gasegase o le mafaufau. Faʻatusatusaga o tagata mamaʻi ma faʻatonutonu. Arch Gen Psychiatry 1991; 48: 540-547. Vaʻai faʻamatala.
109. Halladay, AK, Wagner, GC, Sekowski, A., Rothman, RB, Baumann, MH, ma Fisher, H. Suiga i le inu ava malosi, tosoina o le faoa faamalosi, ma le feaveaʻi o le monoamine i isumu e togafitia i le phentermine ma le 5-hydroxy-L-tryptophan . Synaps 2006; 59: 277-289. Vaʻai faʻamatala.
110. Curcio, J. J., Kim, L. S., Wollner, D., ma Pockaj, B. A. O le gafatia o le 5-hydryoxytr Egyptophan mo le faʻaitiitia o le vevela: o se manatu. Altern Med Rev 2005; 10: 216-221. Vaʻai faʻamatala.
111. Victor, S. ma Ryan, S. W. Fualaʻau mo le puipuia o le ulu o le ulu i tamaiti. Cochrane Database.Syst.Rev 2003;: CD002761. Vaʻai faʻamatala.
112. George DT, Lindquist T, Rawlings RR, et al. Togafitiga o le falemaʻi o le faʻamamaina i tagata mamaʻi ma le ava malosi: leai se aoga o le 5-hydroxytryptophan poʻo le levodopa Clin Pharmacol Ther 1992; 52: 553-60. Vaʻai faʻamatala.
113. Shaw, K., Turner, J., ma Del Mar, C. Tryptophan ma le 5-hydroxytr Egyptophan mo le faʻanoanoa. Cochrane Database.Syst Rev 2002;: CD003198. Vaʻai faʻamatala.
114. Ciaranello, R. D., Anders, T. F., Barchas, J. D., Berger, P. A., ma Cann, H. M. O le faʻaaogaina o le 5-hydroxytr Egyptophan i se tamaititi ua maua i le Lesch-Nyhan syndrome. Tamaiti Psychiatry Hum Dev 1976; 7: 127-133. Vaʻai faʻamatala.
115. Anderson, L. T., Herrmann, L., ma Dancis, J. O le aafiaga o le L-5-hydroxytr Egyptophan i le tagata lava ia o le mutilatin i le gasegase o Lesch-Nyhan: o se lipoti le lelei. Neuropadiatrie 1976; 7: 439-442. Vaʻai faʻamatala.
116. Growdon, J. H., Young, R. R., ma Shahani, B. T. L-5-hydroxytr Egyptophan i togafitiga o le tele o syndrome eseese o loʻo lauiloa ai le myoclonus. Neurology 1976; 26: 1135-1140. Vaʻai faʻamatala.
117. Takahashi S, Kondo H, Kato N. Aafiaga o l-5-hydroxytr Egyptophan luga o le faiʻai monoamine metabolism ma le iloiloga o lona togafitiga aʻafiaga i tagata mamaʻi faʻanoanoa. J Psychiatr Res 1975; 12: 177-87. Vaʻai faʻamatala.
118. Preshaw RM, Leavitt D, Hoag G. O meaʻai faʻaopopo 5-hydroxytr Egyptophan ma urinary 5-hydroxyindole acetic acid. CMAJ 2008; 178: 993. Vaʻai faʻamatala.
119. Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5-Hydroxytr Egyptophan: o se toe iloiloga o lona antidepressant aoga ma aʻafiaga leaga. J Clin Psychopharmacol 1987; 7: 127-37 .. Seʻi vaʻaia.
120. Shaw K, Turner J, Del Mar C. Tryptophan ma le 5-hydroxytr Egyptophan mo le faʻanoanoa. Cochrane Database Syst Rev 2002;: CD003198. Vaʻai faʻamatala.
121. Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V. Faʻalua-tauaso suʻesuʻega o le 5-hydroxytr Egyptophan ma le placebo i le togafitiga o le muamua fibromyalgia syndrome. J Int Med Res 1990; 18: 201-9. Vaʻai faʻamatala.
122. Johnson KL, Klarskov K, Benson LM, et al. Le iai o le tumutumu X ma isi fesoʻotaʻiga: o le lipoti faʻaleagaina i le mataupu fesoʻotaʻi 5-hydroxy-L-tryptophan fesoʻotaʻi ma eosinophilia-myalgia syndrome. J Rheumatol 1999; 26: 2714-7. Vaʻai faʻamatala.
123. Singhal AB, Caviness VS, Begleiter AF, et al. Cerebral vasoconstriction ma le stroke ina ua maeʻa ona faʻaaogaina vailaʻau serotonergic. Neurology 2002; 58: 130-3. Vaʻai faʻamatala.
124. U. S. Meaʻai ma Vailaau Faʻafoeina, Nofoaga mo Meaʻai Saogalēmū ma Faʻatagaina Meaʻai, Ofisa o Meaʻai Meaʻai, Faʻailogaina, ma Meaʻai Faʻatumu. Faʻamatalaga Pepa i L-Tryptophan ma 5-hydroxy-L-tryptophan, Fepuari 2001.
125. Nardini M, De Stefano R, Iannuccelli M, et al. Togafitiga o le faʻanoanoaga ma L-5-hydroxytryptophan tuʻufaʻatasia ma le chlorimipramine, o se lua-tauaso suesuega. Int J Clin Pharmacol Res 1983; 3: 239-50. Vaʻai faʻamatala.
126. Ribeiro CA. L-5-Hydroxytr Egyptophan i le faʻamatalaga o le faʻaumiumi o le feteʻenaʻi-ituaiga ulu: o faʻalua-tauaso, faʻasolosolo, placebo-pulea suesuega. Ulu o le ulu 2000; 40: 451-6. Vaʻai faʻamatala.
127. Poldinger W, Calanchini B, Schwarz W. O se auala aoga i le atuatuvale: serotonin deficit as a target syndrome i le faʻatusatusaga o le 5-hydroxytr Egyptophan ma le fluvoxamine. Psychopathology 1991; 24: 53-81. Vaʻai faʻamatala.
128. Sternberg EM, Van Woert MH, Young SN, et al. Atinaʻeina o se scleroderma-pei maʻi i le taimi o togafitiga ma L-5-hydroxytr Egyptophan ma carbidopa. N Engl J Med 1980; 303: 782-7. Vaʻai faʻamatala.
129. U.S. Taumafa ma Vailaau Faʻafoeina. Le mama na faʻamaonia i meaʻai supa 5-hydroxy-L-tryptophan. Pepa Talanoa a le FDA, Aukuso 31, 1998; T98-48.
130. Meyer JS, Welch KM, Deshmukh VD, et al. Neurotransmitter precursor amino acids i le togafitia o le tele-infarct dementia ma le Alzheimer faamaʻi. J Amer Geriat Soc 1977; 25: 289-98. Vaʻai faʻamatala.
131. Trouillas P, Brudon F, Adeleine P. Faʻaleleia atili o le cerebellar ataxia ma levorotatory form o 5-hydroxytr Egyptophan: o se lua-tauaso suʻesuʻega ma le aofaʻi o faʻamatalaga gaosi. Arch Neurol 1988; 45: 1217-22. Vaʻai faʻamatala.
132. Kahn RS, Westenberg HG. L-5-hydroxytr Egyptophan i le togafitia o faʻalavelave popole. J Faʻafitauli le lelei 1985; 8: 197-200. Vaʻai faʻamatala.
133. Cangiano C, Ceci F, Cancino A, et al. Amioga 'ai ma le usitaʻia o faʻatonuga o meaʻai i mea lapopoʻa tagata matutua mataupu faʻataʻitaʻia ma le 5-hydroxytr Egyptophan. Am J Clin Nutr 1992; 56: 863-7. Vaʻai faʻamatala.
134. Sarzi Puttini P, Caruso I. Peraimeri fibromyalgia syndrome ma 5-hydroxy-L-tryptophan: o se 90-aso tatala suʻesuʻega. J Int Med Res 1992; 20: 182-9. Vaʻai faʻamatala.
135. Nakajima T, Kudo Y, Kaneko Z. Suʻesuʻega faʻafomaʻi o le 5-hydroxy-L-tryptophan o se vailaʻau antidepressant. Folia Psychiatr Neurol Jpn 1978; 32: 223-30. Vaʻai faʻamatala.
136. Michelson D, Itulau SW, Casey R, et al. O le eosinophilia-myalgia syndrome e fesoʻotaʻi ma le le atoatoa e fesoʻotaʻi ma le aafia i le L-5-hydroxytr Egyptophan. J Rheumatol 1994; 21: 2261-5. Vaʻai faʻamatala.
137. Birdsall TC. 5-Hydroxytr Egyptophan: O Se Fomaʻi-Lelei Aʻoaʻoga Serotonin. Altern Med Rev 1998; 3: 271-80. Vaʻai faʻamatala.

Toe iloiloga - 12/29/2020